흰쥐 이자 Insulin과 Neuropeptide Y 분비세포의 발생에 관한 면역조직화학적 연구

장인엽,박태우,정윤영,김종중,문정석,김영택,안계훈,김남훈,선희매 조선대학교 부설 의학연구소 1999 The Medical Journal of Chosun University Vol.24 No.1

Cells immunoreactive to insulin(INS-IR) and neuropeptide Y(NPY-IR) were found in prenatal(E15, 17, 19) and postnatal(P0, 5, 10, 15, 30, adult) rat pancreas using immunohistochemistry. Pancreatic INS-IR and NPY-IR were detected by day E17. They were found initially in the interlobular pancreatic duct, intralobular pancreatic duct and pancreatic islet gradually. Especially, INS-IR was detected in the dorsal pancreatic bud by day E19. The INS-IR and NPY-IR patterns were nearly similiar to each other, and many cells revealed colocalization of INS and NPY until day P10. But there was a change between them by the day P15 ; central INS-IR cells and peripheral NPY-IR in the pancreatic islet. The number of pancreatic islets per square millimeter of pancreatic tissue were decreased, and the number of immunoreactive endocrine cells per islet was increased according to development. These results suggest NPY may play a role in the development of the pancreatic endocrine cells.

법랑모세포 분화와 성숙과정에서 OD314의 발현

박주철,안성민,김흥중,정문진,박민주,신인철,손호현 大韓齒科保存學會 2005 Restorative Dentistry & Endodontics Vol.30 No.5

법랑모세포는 법랑질을 형성하고 유지하는 세포로, 법랑질의 유기기질을 분비하고 법랑질 석회화 과정에도 관여한다. 치아 발생과정에서 법랑모세포의 분화는 순차적인 상피-간엽 상호작용에 의하여 조절되나, 분화나 성숙과정의 정확한 기전은 아직까지 잘 알려져 있지 않다. 최근에 상아모세포에서 처음 발견된 OD314가 치아 발생과정에서 상아질을 형성하는 상아모세포 뿐 아니라 법랑모세포에도 발현된다고 하였다. 이에 본 연구에서는 생쥐 하악 전치의 다양한 시기의 법랑모세포를 이용하여, 형태학적 분석과 in-situ hybridization에 의한 OD314 mRNA의 발현 그리고 OD314 항체를 이용한 면역조직화학적 분석을 통하여 OD314 유전자의 법랑 모세포 분화와 성숙과정에서의 역할을 연구하여 다음과 같은 결과를 얻었다. 1. 형태학적으로 법랑모세포는 분화 단계에 따라 분비 전단계 법랑모세포, 분비기 법랑모세포, 성숙기의 평탄끝 법랑모세포와 성숙기의 주름끝 법랑모세포로 구분되었다. 2. OD314 mRNA는 분비기의 법랑모세포에서부터 발현되기 시작하여 법랑모세포가 성숙해갈 수록 그 발현이 증가하였다. 3. OD314 단백질은 분비 전단계의 법랑모세포에서는 발현되지 않고, 분비기의 법랑모세포에서는 세포질에 전체적으로 발현되었다. 성숙기의 평탄끝 법랑모세포와 주름끝 법랑모세포에서는 세포의 근심과 원심끝단에 OD314 단백질이 강하게 발현되었다. 이상의 결과를 종합하여 OD314는 법랑모세포의 분화와 성숙과정에서 세포질 내부에서 특징적인 역할을 하는 것으로 사료된다. Ameloblasts are responsible for the formation and maintenance of enamel which is an epithelially derived protective covering for teeth. Ameloblast differentiation is controlled by sequential epithelial-mesenchymal interactions. However, little is known about the differentiation and maturation mechanisms. OD314 was firstly identifled from odontoblasts by subtraction between odontoblast/pulp cells and osteoblast/dental papilla cells, even though OD314 protein was also expressed in ameloblast during tooth formation. In this study, to better understand the biologcal function of OD314 during amelogenesis, we examined expression of the OD314 mRNA and protein in various stages of ameloblast differentiation using in-situ hybridization and immunohistochemistry. The results were as follows : 1. The ameloblast showed 4 main morphological and functional stages referred to as the presecretory, secretory, smooth-ended, and ruffle-ended. 2. ○D314 mRNA was expressed in secretory ameloblast and increased according to the maturation of the cells. 3. OD314 protein was not expressed in presecretory ameloblast but expressed in secretory ameloblast and maturative ameloblast. OD314 protein was distributed in entire cytoplasm of secretory ameloblast. However, OD314 was localized at the proxiamal and distal portion of the cytoplasm of smooth- ended and ruffle-ended ameloblast. These results suggest that ○D314 may play important roles in the ameloblast differentiation and maturation.

개 이자의 Somatostatin 양성세포의 발달에 관한 면역조직화학적 연구

장인엽,윤상필,정윤영,김종중,문정석,한길현,김영택,안계훈,선희매 조선대학교 부설 의학연구소 1998 The Medical Journal of Chosun University Vol.23 No.2

Cells immnunoreactive for somatostatin(SOM) and glucagon(GLU) were investigated in postnatal day 0, 7, 14, 28, 90, 180 and adult canine pancreas using light microscopic immunohistochemistry. Pancreatic SOM-immunoreactive cells were found in pancreatic acini, pancreatic duct, and pancreatic islet gradually. Pancreatic SOM-immunoreactive cells were more located in pancreatic parenchyme than pancreatic islet throughout pancreas by postnatal day 28. But there was change by the postnatal 3 months : pancreatic SOM-immunoreactive cells were more located in pancreatic islet than acini and duct. It is suggested that the number of the SOM-immunoreactive cells may not increase with age apparently. A small number of SOM-immunoreactive cells that showed GLU-immunoreactivity were also observed in canine pancreatic islet. The physiologic consequences of these changes remain to be determined. These results sugegest that SOM in the developing pancreas may relate to the secretion of pancreatic hormones.

자가 말초혈액 조혈모세포 이식술의 임상적용

김혁,안명주,오석중,이영열,김인순,정태준,최일영,오미란,임호준,이항,김신규 한양대학교 의과대학 1999 한양의대 학술지 Vol.19 No.1

Responses to chemotherapy correlate with the increased dose of chemotherapeutic agents in some cancers, e.g. breast cancer, Ewing's sarcoma, Hodgkin's disease(HD) and non-Hodgkin's lymphoma(NHL), then for the improvement of the chemotherapy responsiveness, high-dose chemotherapy(HDCT) was proposed. But, it's application was limited due to complications, especially bone marrow suppression. HDCT and succeeding autologous peripheral blood stem cell transplantation(APBSCT) was introduced to overcome this problem. This study was designed to determine the clinical pictures including clinical parameters and the responsiveness of HDCT followed by APBSCT in Hanyang University Hospital. Ten patients were enrolled. They were 8 adults (3 breast cancers, 3 multiple myelomas, 1 HD, 1 NHL) and 2 children (1 acute myelogenous leukemia (AML), 1 neuroblastoma). Mobilization chemocherapy(MCT) followed by Granulocyte Colony Stimulating Factor(G-CSF) was administered to mobilize stem cells from bone marrow to peripheral blood. The stem cells were collected by using CS-3000 and cryopreserved at -196℃ with programmed controlled rate freezer as the mixture with 10% dimethyl sulfoxide(DMSO). HDCT was administered and cryopreserved peripheral stem cells were infused on day 0 as planned. Patients' mean age was 41 years old. After induction chemotherapy three patients achieved complete response and 5 partial response. The median time for bone marrow recovery after MCT was 11.5 days for neutrophil(〉500/㎣) and 4.8 days for platelet(〉20,000/㎣). There were three cases of neutropenic fever and one case of gingivitis. After HDCT with APBSCT, one patient was converted partial response to complete response, and one patient achieved complete response after HDCT without induction chemotherapy. The median time for bone marrow recovery was 12.7 days for neutrophil(〉500/㎣) and 14.7 days for platelet(〉20,000/㎣). Eight patients developed neutropenic fever and required systemic antibiotics. Transfusion was required 1.6 pints for packed red cell and 23.4 pints for platelet concentrates. Toxicity consisted mainly of vomiting, diarrhea, and mucositis which were mild. HDCT with APBSCT can be performed safely with minimal complications. For the evaluation of the exact role of HDCT with APBSCT in malignant diseases, further studies are required as a large scale of patients and lung-term follow up.

악성 질환에서의 고용량 화학요법과 자가말초혈액 조혈모세포이식술 : 단일기관 치료 경험

최정혜,안명주,오호석,이웅수,오석중,이영열,최일영,김인순 대한조혈모세포이식학회 2003 대한조혈모세포이식학회지 Vol.8 No.2

연구배경: 고용량 화학요법은 항암제의 투여 용량에 따라 항암효과가 비례하는 용량반응 관계가 있는 악성종양에서 효과를 기대할 수 있으며 현재 급성백혈병, 악성림프종, 다발성골수종 등의 혈액 종양과 유방암, 고환암, 난소암, 신경아세포종 등의 고형암 환자에서 시행되고 있다. 저자들은 고용량화학요법에 이어 자가조혈모세포이식을 시행 받은 악성 종양 환자를 대상으로 치료효과 및 부작용 등의 임상상을 알아보고자 하였다. 방법: 1997년부터 2003년까지 한양대학교 병원에서 자가조혈모세포이식을 시행 받은 악성 종양 환자 31예(남서 : 여성 15 : 16, 중앙연령: 50세, 다발성골수종 14예, 비호지킨림프종 9예, 유방암 4예, 호지킨림프종 3예, 급성골수성백혈병 1예)를 대상으로 후향적 분석을 시행하였다. 결과: 채집된 단핵구의 중앙값은 5.1×10^(8)/kg (범위 1.6~189.3)이었고 CD34양성세포수의 중앙값은 12.0×10^(6)/kg (범위 1.3~75.1)이었다. 말초혈액 과립구가 500/μL 에 도달하는 중앙값은 11일(범위 8~27)이었고 혈소판이 20,000/μL에 도달하는 중앙값은 11일(범위 0~32)이었다. 고용량 항암화학요법 후 21예가 완전관해, 5예가 부분관해에 도달하였다. 생존한 환자의 중앙추적기간은 29.5개월이었고 전체 환자의 2년 무병생존기간은 55.7%이었고 중앙값은 48.2개월이었다. 2년 생존기간은 62.9%이었으며 중앙값에는 도달하지 않았다. 10예의 사망환자 중 7예가 질병의 진행으로 사망하였고, 조기사망 3예(심부전과 신부전 1예, 장파열 1예, 패혈증 1예)가 있었다. 결론: 이 연구는 포함된 환자의 수가 적고 추적기간이 짧은 단점이 있으나, 다발성골수종, 악성림프종 등의 악성 질환에서 고용량 항암화학요법과 자가조혈모세포이식은 안전하고 효과적인 치료임을 추정할 수 있었다. Background: We performed the current study to evaluate the safety and efficacy of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (ASCT) in malignant diseases. Methods: Between January 1997 and March 2003, 31 patients (14 multiple myeloma, 9 Non-Hodgkin's lymphoma, 3 Hodgkin's disease, 4 breast cancer, and 1 acute myelogenous leukemia) underwent HDC with ASCT. Stem cells were collected by CS-3000 after mobilization treatment with chemotherapy and granulocyte colony-stimulating factor. The conditioning regimens included high-dose melphalan, BEAM (BCNU, etoposide, cytosine arabinoside, melphalan), BEAC (BCNU, etoposide, cytosine arabinoside, cyclophosphamide), CPB (cyclophosphamide, cisplatin, BCNU) and others. Results: There were 15 male and 16 female patients and median age was 50 years (range: 29~77). The median number of mononuclear and CD34+ cells was 5.1×10^(8)/kg (1.6~189.3) and 12.0×10^(6)/kg (1.3~75.1), respectively. The median time of neutrophil (>500/μL) and platelet (>20,000/μL) engraftment was 11 (8~27) and 11 (0~32) days after ASCT, respectively. Twenty-two patients experienced neutropenic fever. Twenty-one patients achieved complete remission and 5 patients achieved partial remission after HDC with ASCT. The median follow-up duration for surviving patients was 29.5 months. Causes of death included disease progression (7), sepsis (1), bowel perforation (1), and renal failure (1). Median progression free survival (PFS) was 48.2 months and median overall survival (OS) was not reached. Two-year PFS and OS was 55.7% and 62.9%, respectively. Conclusion: Our results suggest that HDC with ASCT was safe and effective modality in patients with various malignant diseases.

급성 경항통 환자의 흉쇄유돌근에 대한 근 에너지 기법(MET) 시술 후의 경근전도 변화 연구

안재민 ( Jae Min Ahn ),조동인 ( Dong In Cho ),박동수 ( Dong Su Park ),정수현 ( Su Hyeon Jeong ),김순중 ( Soon Joong Kim ) 한방재활의학과학회 2014 한방재활의학과학회지 Vol.24 No.1

ObjectivesTo evaluate the clinical utility of MET performed on sternocleidomastoid mus-cle of acute nuchal pain patients, we measured a change of meridian electromyography.MethodsWe compared electrical activity before and after MET performed on sternoclei-domastoid muscle of acute nuchal pain patients in same group (n=20) in isometric exercise state during five seconds. We analyzed amplitudes and areas of electrical activity and asymmetry index (AI).Results1. After MET performed on sternocleidomastoid muscle of acute nuchal pain pa-tients, maximum voluntary isomeric contraction (MVIC) was significantly increased more than before MET performed (p<0.005). 2. Comparing with before MET performed on ster-nocleidomastoid muscle of acute nuchal pain patients, muscle fatigue after MET performed on sternocleidomastoid muscle of acute nuchal pain patients decreased but there was no significant difference. 3. Comparing with before MET performed on sternocleidomastoid muscle of acute nuchal pain patients, asymmetry index (AI) after MET performed on sterno-cleidomastoid muscle of acute nuchal pain patients decreased but there was no significant difference.ConclusionsAccording to above results, after performing MET on sternocleidomastoid muscle of acute nuchal pain patients, maximum voluntary isomeric contraction (MVIC) in-creased significantly, so it is certain that performing MET on sternocleidomastoid muscle has a clinical effect. (J Korean Med Rehab 2014;24(1):93-100)

흰쥐 뇌에서 Tyrosine Hydroxylase분비세포의 출현시기 및 분포에 관한 면역조직화학적 연구

정윤영,선희매,김영택,김남훈,안계훈,장인엽,김종중,문정석,강양수 조선대학교 부설 의학연구소 1999 The Medical Journal of Chosun University Vol.24 No.1

The immunohistochemical (ABC method) studies on the ontogeny and localization of the catecholamine-synthesizing enzyme tyrosine hydroxylase (TH) were examined in rat brain from the 12th fetal day until the 9th postnatal day. The results obtained were as follows : 1. Tyrosine hydroxylase was first detected immunohistochemically at embryonic day 13(E13). At this stage, the TH-containing neurons were still migrating and cytologically immature. 2. The changes occuring from the early to the late prenatal stages of development appeared to be the result of an increase in the number and size of the TH-containing cells and in the length of nerve fibers. 3. The distribution of the TH-containing neurons at embryonic day 19(E19) more closely resembled catecholaminergic neurons in the adult rat brain : 1) a rhombencephalic group became the A1-7 ; 2) a ventral mesencephalic group became A8-10 ; 3) a ventral prosencephalic group and a few neurons ventral to the striatum became A11-14 ; and 4) the cells of the olfactory bulb corresponded to the A15. 4. The cytodifferentiation of the TH-immunoreactive neurons was accompanied by continued migration to form the collective catecholaminergic groups during ontogenesis. In addition, the morphology of the TH-immunoreactive neurons in the late prenatal stage resembled in the adult rat brain.

Interleukin-2를 이용한 진행성 위장관암의 비장을 경유한 자가 LAK Cell의 면역학적 반응

안우섭,강중신,김인호,전석길,손수상 啓明大學校 醫科大學 1993 계명의대학술지 Vol.12 No.3

To elucidate the anticancer effect by observing the effect of LAK cells after infusion of IL-2 through splenic artery for the advanced gastrointestinal cancer, randomized study was performed for the 8 patients who had liver metastasis from gastic and rectal cancer. 4 patients were performed subtotal gastrectomy for stomach cancer and the others were done abdominoperineal resections for rectal cancer. The liver metastasis were noted all of the cases after surgery between October 1989 and December 1992 at the Department of Surgery, Keimyung University School of Medicine. After confirmation of the hepatic metastasis from gastorintestinal cancer, we performed selective splenic arterial infusin of IL-2 with the dosage of 20,000 units/kg B.W. We checked the immune function pre-and post-IL2 infusion therapy, such as total lymphocyte count, T-cell percentage and CMI multitest with blood count and hepatorenal function. There was no difference between the pre-and post IL-2 infusion in the hemoglobin, serum protein, albumin, BUN and creatinin. The total lymphocyte counts of pre-and post IL-2 infusion were 1641.2 and 1727.4, respectively. The T cell percentage of pre-and infusion were 62.51% and 64.27%, respectively and had the tendency to increase in comparison with pre-IL-2 infusion, but there were not stastical differences. The results of CML muiltitest of pre-and post IL-2 infusion were not definite differences. From the above results, it could be suggested that LAK cell after infusion of IL-2 via selective splenc artery had the slightly positive effect of the immune function of advanced gastrointestinal cancer patient, with hepatic metastasis.

개질 천연 고분자 응집제에 관한 연구

이순홍,김대인,배중돈,안광호 안양대학교 산업기술연구소 2000 自然科學硏究 Vol.7 No.-

수용성 고분자 chitosan은 폐수로부터 현탁물질을 처리하기 위한 효과적인 응집제로 유용하게 사용될 수 있다. chitosan은 충분한 양을 확보할 수 있고 무독성이며 2차 오염이 없어 응집제로서 매우 유용하다. 본 연구의 목적은 고기능성 신소재인 분자량 분획 수용성 고분자 chitosan을 분자량별로 각각 100㎎/ℓ로 제조하여 0.1wt%-kaolin 현탁액, 0.1wt%-egg albumin 제조폐수 및 두부공장폐수에 응집제로 사용하여 최적 적용 조건을 검토하였다. 모든 폐수의 응집을 위한 최적 pH는 5, 제조폐수의 응집처리 후 상등액의 투과율은 모두 95% 이상, 두부공장폐수는 약 80%의 투과율을 나타내었다. chitosan blendmer의 경우 chitosan과 CMC(100㎎/ℓ)의 혼합비가 2 : 1 일 때 응집효과가 가장 뛰어났다. Chitosan modified natural polymers can be used as an effective coagulant for the removal of suspended and dissolved solids from wastewater, and doesn't occurred secondary pollution. The present investigation was to evaluate optimum condition for treatment of suspended and dissolved solids from wastewater using plain chitosan and modified chitosan blendmer. Optimum condition for coagulating kaolin suspension, egg albumin suspension and tofu wastewater was pH 5. The highest transmittance of 0.1wt%-kaolin suspension, 0.1wt%-egg albumin suspension and tofu wastewater showed 98.4%(at Mw 800,000Cs), 96.38%(at Mw 200,000Cs) and 79.62%(at Mw 400,000Cs), respectively. In case of chitosan blendmer (CMC : Cs = 1 : 2) the highest transmittance of 0.1wt%-kaolin suspension, 0.1wt%-egg albumin suspension and tofu wastewater showed 95.94%(at Mw 800,000Cs), 95.06%(at Mw 200,000Cs) and 78.38%(at Mw 400,000Cs), respectively.

랫드에서 단일시험법을 이용한 반하 물추출물의 생식독성시험

이기남,유욱준,백인정,연정민,남상섭,이범준,남상윤,김윤배,강현규,안병우,김대중,황방연,노재섭,홍정섭,성하정,김순선,조대현,윤영원 충북대학교 동물의학연구소 2006 Journal of Biomedical and Translational Research Vol.7 No.1

본문참조